Two people can take the same cannabis oil for the same kind of chronic pain and end up in very different places. One manages work, sleep and family life; the other feels flattened by low mood and a body that keeps saying no. A fresh study from Brazil suggests that part of the difference may lie not in the bottle but in the person: a sense of coherence in medical cannabis patients with chronic pain was linked to noticeably less depression and less disruption of daily life.
The cross-sectional study, written by researchers from the Federal University of São Paulo and the Federal University of Sergipe, was published online in the Journal of Psychiatric Research at the end of October 2026. It surveyed 156 patients who receive cannabis through five Brazilian patient associations. We read it alongside an earlier US study of people with muscle and joint pain, which this article first covered and which we have kept and corrected below, because together the two pieces of research tell a more complete story: one asks whether medical cannabis helps chronic pain, the other asks why some patients still struggle while using it.
Key Takeaways
Among 156 Brazilian adults with chronic pain using medical cannabis, mostly middle-aged women taking THC-rich cannabis oil for more than six months, pain intensity was on average mild, but pain still interfered moderately with daily life, depression and anxiety scores sat in the moderate range, and physical quality of life was rated low. Patients with a strong sense of coherence, meaning the feeling that life is understandable, manageable and worth the effort, had clearly lower depression scores and less pain interference than patients with a weak one. The study is a single snapshot without a comparison group, so it cannot show that cannabis or a sense of coherence caused anything. The earlier US study of 129 long-term medical cannabis patients with muscle and joint pain found that more than 93% felt cannabis improved their main symptom and 72.1% reported no effect on thinking or coordination, but it relied entirely on self-reported answers. Read together, the two studies suggest that symptom relief and overall wellbeing are not the same thing, and that a patient’s psychological resources may matter for how they fare on treatment.
Sense of coherence in medical cannabis patients with chronic pain: the Brazilian survey
The research team recruited patients through five cannabis patient associations in Brazil. These are nonprofit groups that produce or distribute cannabis oil to registered members, a route many Brazilian patients use alongside the pharmacy products regulated by the national health agency. Participants filled in an online survey that bundled several standard questionnaires:
- the SOC-13 scale, a 13-question test of sense of coherence
- the Brief Pain Inventory, which separates how strong pain is from how much it gets in the way of life
- the DASS-21, a short screen for depression, anxiety and stress
- the Pittsburgh Sleep Quality Index, a common sleep questionnaire
- the WHOQOL-BREF, the World Health Organization’s short quality-of-life questionnaire
The typical participant was a white, middle-aged woman who had been using THC-rich cannabis oil for more than six months. That profile matters: it tells us who the results describe, and who they may not.
What is a sense of coherence?
Sense of coherence is the central idea of salutogenesis, a way of looking at health developed by the Israeli-American sociologist Aaron Antonovsky. Instead of asking what makes people sick, salutogenesis asks what keeps people well under pressure. Antonovsky’s answer was a general orientation to life built from three parts: comprehensibility (things that happen to me make some sense), manageability (I have, or can find, the resources to cope) and meaningfulness (it is worth investing effort in dealing with this).
A useful picture is a sailor in rough water. The storm is the same for everyone on deck, but the person who can read the sea, knows where the ropes are and believes the voyage is worth it will handle the waves differently from someone who feels lost. Chronic pain is a long storm, and the sense of coherence describes how well-equipped a person feels to sail through it. Antonovsky believed it settles in early adulthood, though later research suggests it can still shift with life circumstances.
On the SOC-13 scale, scores can range from 13 to 91. The Brazilian patients averaged 52.64 (standard deviation 12.40), which places them around the middle of the possible range.
Pain, mood and quality of life in the Brazilian sample
The headline numbers paint a mixed picture. Average pain intensity was mild, at 3.99 on a 0 to 10 scale (standard deviation 2.60). Pain interference, the measure of how much pain disrupts work, mood, sleep and relationships, was higher and rated moderate, at 4.48 (standard deviation 3.16).
Emotional health was where the strain showed most. Depression scores averaged 13.82 (standard deviation 12.04) and anxiety scores 10.30 (standard deviation 9.72), both in the moderate range by the authors’ classification, while stress averaged 16.28 (standard deviation 11.32), rated mild. Quality of life was low in the physical domain, at 2.91 on a scale where 5 is the best (standard deviation 0.82), and fair in the psychological, social and environmental domains.
In plain terms, these were patients whose pain was, on average, under reasonable control, yet who still carried a noticeable load of low mood, worry and physical limitation. That gap between pain scores and wellbeing is exactly what makes the link between chronic pain and mental health worth studying in cannabis patients.
The study also measured sleep quality, but the published abstract does not report those results, and we have not been able to review the full paper behind the publisher’s paywall. Our summary is based on the abstract.
Stronger coherence, less depression and less pain interference
The most interesting result came when the researchers split participants into two groups, those with a strong sense of coherence and those with a weak one, and compared them. Patients with a strong sense of coherence had markedly lower depression scores (p < 0.001, effect size r = 0.6) and less pain interference (p < 0.001, r = 0.4).
What do those numbers mean? The p-value says the difference is very unlikely to be a fluke of chance in this sample. The effect size r says how big the difference is: by common rules of thumb in psychology, 0.6 counts as a large effect and 0.4 as a medium one. So this was not a hair’s-breadth difference buried in statistics. In this group of patients, people who felt their lives were understandable and manageable were, on average, considerably less depressed and less hemmed in by their pain.
The authors concluded that among people using medical cannabis, a stronger sense of coherence went together with better health outcomes, particularly for mental health, even with a chronic stressor like ongoing pain. They point to salutogenic resources, the inner and outer supports that help people cope, as potentially relevant for patients living with chronic illness.
For readers wondering how to deal with chronic pain mentally, the practical takeaway is modest but real: wellbeing in chronic pain seems to depend on more than how strong the pain is or which product someone uses, and the coping resources a person has may deserve as much attention as the dose.
What this study cannot tell us
Several limits shape how far these findings can go.
The design is cross-sectional: everyone was surveyed once, at a single point in time. That means the study can show that two things travel together, but not which comes first. A strong sense of coherence might protect against depression, but it is just as plausible that people who are less depressed simply rate their lives as more manageable. Both readings fit the data.
There was no comparison group of chronic pain patients who did not use cannabis. So the study cannot tell us whether cannabis improved mood, worsened it or had no effect. It describes people on medical cannabis; it does not test medical cannabis.
The sample was 156 people reached through patient associations and an online survey, which favors those who are connected, motivated and comfortable online. Most were white, middle-aged women using THC-rich oil, so the results may not transfer to men, older or younger patients, or people using other products. The authors themselves describe the strong-versus-weak comparisons as exploratory, which is scientific shorthand for “worth following up, not yet settled.”
The earlier US study: medical cannabis for musculoskeletal pain
This article originally covered a US study of medical cannabis for chronic muscle and joint pain, and that research still matters. Musculoskeletal conditions affect bones, joints, muscles, ligaments and other connective tissues. According to the World Health Organization, about 1.71 billion people live with such conditions worldwide, and they are the leading contributor to disability globally.
Pain from musculoskeletal conditions can limit mobility, reduce quality of life and interfere with daily activities. Common causes include arthritis, back pain, tendonitis and injuries like sprains and fractures. For many patients, physical therapy, over-the-counter pain relievers or prescription opioids fall short or come with significant side effects.
The research, published in the journal Cureus in May 2025 by a team from the Rothman Orthopaedic Institute and Thomas Jefferson University in Philadelphia, followed 129 adults in Pennsylvania who had been certified for medical cannabis for chronic, non-cancer musculoskeletal pain for at least one year. They answered a questionnaire about how they use cannabis, which forms they prefer, and how it affects their pain and daily functioning. Among the findings:
- 77.5% had been using medical cannabis for more than two years, and 77.5% used it daily or near daily
- 63.5% consistently used topical products such as creams and balms, the most common form
- 93.7% agreed or strongly agreed that cannabis improved their main symptom
- 72.1% said cannabis had no effect on their thinking or coordination
- 79.8% reported stable use over the previous three months
- roughly half did not know how much THC or CBD they took by mouth
- 99.2% said no friend, family member, coworker or healthcare provider had suggested they cut back
THC (tetrahydrocannabinol) is the main intoxicating compound in cannabis and is thought to contribute to its pain-relieving effects; CBD (cannabidiol) does not cause a high and is studied for pain, anxiety and inflammation. The fact that so many patients did not know their dose, which the authors partly blame on poor product labeling, is one of the study’s more practical warnings. For a deeper look at the compound, our science-based CBD guide covers what is and is not known.
A safe alternative to traditional pain medications?
The US authors concluded that long-term medical cannabis use was stable and well tolerated in their patients, with high self-reported benefit and little cognitive impact. They also listed serious caveats: everything was self-reported, there was no control group, doses, strains and other medications varied widely, and stigma or legal worries may have led some patients to under-report side effects. They called for further research on optimal dosing and long-term safety. One more limit is built into the design: the survey only reached people who had stayed on cannabis for at least a year, and patients for whom it did not work were less likely to still be in the program.
That framing still holds. Surveys like this one show how patients experience cannabis, not whether it outperforms other treatments. Controlled trials give a more mixed picture: our report on a trial comparing cannabis with ibuprofen for chronic pain found the THC component mattered, while a review of cannabinoids for rheumatoid arthritis pain turned up only three clinical studies and a single randomized trial. Researchers are also experimenting with new formulations, such as nano-sized CBD particles for chronic pain, but that work is at an early stage.
Expert reaction: cannabis’ expanding role in pain management
Paul Armentano, deputy director of the US advocacy group NORML, commented on the Pennsylvania study that it adds to the evidence that cannabis is effective for several conditions, including chronic pain, and that it has “a safety profile that is often superior to traditional medications, like opioids.” He added that as legal access grows, more patients can be expected to fold cannabis into their pain management and lean less on opioids. NORML campaigns for cannabis law reform, which is worth keeping in mind when weighing its assessment.
Two studies, one lesson: relief and wellbeing are not the same thing
Put side by side, the two studies look at chronic pain from different angles. The Pennsylvania patients mostly rubbed topical cannabis on sore joints and muscles and reported that it helped. The Brazilian patients mostly took THC-rich oil by mouth, reported fairly mild pain on average, yet many still lived with moderate depression and low physical quality of life.
The Brazilian data hint at something the US survey could not see: feeling better in one area does not automatically lift everything else, and a patient’s inner resources may help decide how much of their life the pain still controls. Neither study proves that cannabis caused any change, and neither can tell an individual what to use. But together they make a case that medical cannabis research for chronic pain should measure more than pain scores, and that care for people with chronic pain should look at mood and coping alongside any medicine. With roughly 3.9 million registered patients across US state programs, according to our overview of US medical marijuana patient statistics, that question is far from academic.
Where medical cannabis for chronic pain stands under US law
In the United States, access depends on the state. Pennsylvania, where the musculoskeletal study took place, runs a medical-only program: residents must be certified by an approved practitioner for one of the serious medical conditions listed by the state Department of Health, which include severe chronic or intractable pain.
At the federal level, the picture changed in April 2026, when the Justice Department placed FDA-approved marijuana products and marijuana covered by a qualifying state medical license in Schedule III of the Controlled Substances Act. All other marijuana, including adult-use cannabis, remains in Schedule I while the broader rescheduling proceeding continues.
FAQ
Sense of coherence is a concept from salutogenesis, an approach to health developed by sociologist Aaron Antonovsky. It describes how far a person sees life as understandable, manageable and meaningful. It is usually measured with questionnaires such as the 13-item SOC-13 scale, and higher scores have been linked in many studies to better mental health under stress.
Clinical trials suggest THC can reduce some types of chronic pain modestly, and patient surveys report high satisfaction, but results vary widely between people and conditions. THC can also cause dizziness, drowsiness and impaired coordination, and it affects driving. Decisions about THC for pain belong in a conversation with a doctor who knows the patient’s history and other medications.
Most evidence on cannabis for joint pain comes from patient surveys, like the Pennsylvania study described above, in which most participants with muscle and joint pain reported improvement. Randomized trials in conditions such as rheumatoid arthritis and osteoarthritis are few and small, so the evidence is promising but far from conclusive.
It depends on the state. Many states with medical programs accept chronic or severe pain as a qualifying condition, but the rules on certification, residency and products differ. Since April 2026, marijuana covered by a qualifying state medical license and FDA-approved marijuana products are in federal Schedule III, while other marijuana remains in Schedule I. Patients should check the current rules of their own state.
Disclaimer
This article is for informational purposes only and does not constitute medical or legal advice. It summarizes published research and does not recommend any treatment, product or dose. Cannabis laws differ between countries and US states and change over time. Anyone considering medical cannabis for chronic pain should speak with a qualified healthcare professional and check the laws that apply where they live.
